Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy

Hepato-Gastroenterology

Volumn 58, Issue 107-108, 2011, Pages 1041-1045

  Kodera, Yasuhiro ^a   Ito, Yuichi ^a   Ohashi, Norifumi ^a   Nakayama, Goro ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Multidrug resistance; Second line chemotherapy; Stomach cancer

Indexed keywords

CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 80051625248     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kang YK, Rang WK, Shin DB, Chen J, Xiong J, Wang J, Lichnitser M, Guan Z, Khasanov R, Zheng L, Philico-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol 2009; 20(4):666-673.
2. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (Spirits trial): a phase III trial. Lancet Oncol 2008; 9(3):215-221.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1):36-46.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Contenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group: Phase III study of docetaxel and ciplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31):4991-4887.
5. Ajani JA, Moisevenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E, V-325 Study Group: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25(22):3210-3216. (Pubitemid 47325603)
6. Ohtsu A, Shimada Y, SHirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluoeouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21(1):54-59.
7. Boku N: Chemotehrapy for metastatic disease: review from JCOG trials. Int J Clin Oncol 2008; 13(3):196-200.
8. Kodera Y, Ito S, Michizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Nakao A, Chubu Clinical Oncology Group: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG 0302 study). Anticancer Res 2007; 27(4C):2667-2671. (Pubitemid 47227980)
9. Hamaguchi T, Shirao K, Yamamichi N, Hyodo I, Koizumi W, Seki S, Imamura T, Honma H, Ohtsu A, Boku N, Mukai T, Yamamoto S, Fukuda H, Yoshida S, Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group: A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group JCOG 9207 trial. Jpn J Clin Oncol 2008; 38(6):432-437. (Pubitemid 351965948)
10. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, Kimura Y, Ishida D, Fujitani K, Narahara H, Shimokawa T: Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 2008; 38(3):176-181. (Pubitemid 351419740)
11. Seo MD, Lee KW, Lim JH, Yi HG, Kim DY, Oh DY, Kim JH, Im SA, Lee JS, Bang YJ: Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol 2008; 38(9):589-595.
12. Lee JL, Ryu MH, Chang HM, Kim TW, Yool JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS, Kang YK: A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008; 61(4):631-637.
13. Calatano V, Graziano F, Santini D, D'Emidio S, Bal-delli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catakano G: Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99(9):1402-1407.
14. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group: N Engl J Med 2007; 357(18):1810-1820.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3):205-216. (Pubitemid 30099779)
16. Theuer CP: Asian gastric cancer patients at a southern California comprehensive cancer center are diagnosed with less advanced disease and have superior stage-stratified survival. Am Surg 2000; 66(9):821-826.
17. Chau I, Norman AR, Ross PJ, Waters JS, Oates J, Cunningham D: Multivariate prognostic factor analysis and second-line treatment in locally advanced and metastatic oesophago-gastric cancer-pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data. ASCO Gastrointestinal Cancers Symposium; abstract 5.
18. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007; 18(5):886-891. (Pubitemid 47054086)
19. Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T: Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72(2):60-64.
20. Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, Kojima H, Kojima T, Matui T, Takase T, Tsuboi K, Fujiwara M, Nakao A for Chubu Clinical Oncology Group: A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG 0301 study). Eur J Surg Oncol 2009; 35(11):1158-63.